Skip to content

阿鲁米斯

US · ALMS #3337 按市值排名 上市于 2024
6.12 -0.19 -3.01%
实时 - 追踪5344个代码 - 心跳于555秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 1.94 处于历史正常水平 第62百分位
5年平均 2.64 · 在Biotechnology中排名第211/513
市盈率 -1.65 高于历史水平 第73百分位
5年平均 -4.62 · 前瞻 -2.19
市销率 118.45 高于历史水平 第69百分位
5年平均 84.02 · 前瞻 200.16 · 在Biotechnology中排名第291/387

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
阿鲁米斯 (ALMS) 792.14M -1.49 1.75 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值5.10 经济护城河None 不确定性Extreme

当前股价高于晨星合理价值估算16.7%。

合理价值

Alumis Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 33% premium over our quantitative fair value estimate of $5.10 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.

The firm's lack of profitability weakens our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 0.9% ranks in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are expensive.

On a different note, the firm's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 6.7, for example, ranks in the top 10% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

阿鲁米斯 讨论区 0 条评论

发表评论